BD, 940285, Oligo Rat Anti-Human CD267 1A1-K21-M22 (also known as 1A1)

The 1A1-K21-M22 monoclonal antibody specifically binds to CD267 which is also known as TACI (Transmembrane Activator and CAML Interactor). CD267 is a member of the of the Tumor Necrosis Factor Receptor (TNFR) Superfamily and is encoded by the TNFRSF13B gene. This 32 kDa type III transmembrane protein receptor binds to the ligands, BAFF (TNFSF13B/BLyS/CD257) and APRIL (TNFSF13/CD256). Ligand-bound CD267 transduces signals leading to the activation of transcription factors including NFAT, AP1, and NF-kappa-B. CD267 is expressed most notably on maturing subsets of B cells and myeloma cells. In CD267 deficient mice, B cell numbers are increased and mice develop autoimmune disorders suggesting that CD267 plays an important role in the regulation of B cell homeostasis.
Put all BD® AbSeq Reagents to be pooled into a Latch Rack for 500 µL Tubes (Thermo Fisher Scientific Cat. No. 4900). Arrange the tubes so that they can be easily uncapped and re-capped with an 8-Channel Screw Cap Tube Capper (Thermo Fisher Scientific Cat. No. 4105MAT) and the reagents aliquoted with a multi-channel pipette. BD® AbSeq tubes should be centrifuged for ≥ 30 seconds at 400 × g to ensure removal of any content in the cap/tube threads prior to the first opening.
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography and conjugated to BD® AbSeq oligonucleotide under optimal conditions.
1. This reagent has been pre-diluted for use at the recommended volume per test. Typical use is 2 µl for 1 × 10^6 cells in a 200-µl staining reaction.
2. Source of all serum proteins is from USDA inspected abattoirs located in the United States.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
4. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
5. Illumina is a trademark of Illumina, Inc.
6. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
7. Please refer to bd.com/genomics-resources for technical protocols.
8. For U.S. patents that may apply, see bd.com/patents.